Summary & Overview
HCPCS J0945: Injection of Brompheniramine Maleate, per 10 mg
HCPCS Level II code J0945 identifies an injection of brompheniramine maleate billed per 10 mg. As an administered antihistamine, this code captures a specific drug dose delivered via injection in outpatient and ambulatory care settings. The code is relevant for clinicians and billing staff who manage medication administration claims and for payers who adjudicate coverage of injected antihistamines.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find national-level context on the clinical role of brompheniramine injections, typical sites of service, and the administrative implications of billing an injected antihistamine. The publication outlines benchmarks and coding guidance, highlights common payer considerations, and summarizes policy updates that affect coverage and claim processing. It also provides a concise reference for clinical and billing teams to understand where J0945 fits within outpatient medication administration workflows.
Data not available in the input for associated taxonomies, specific ICD-10 diagnoses, and related codes.
Billing Code Overview
HCPCS Level II code J0945 denotes an injection of brompheniramine maleate, billed per 10 mg. This code represents a single-dose medication administration of an older-generation antihistamine used for symptomatic relief of allergic conditions.
Service type: Medication injection / administered drug
Typical site of service: Outpatient clinic, physician office, or other ambulatory care settings where intramuscular or subcutaneous injections are provided
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 45-year-old patient presents to an ambulatory infusion clinic with acute severe allergic rhinitis symptoms unresponsive to oral antihistamines and intranasal therapy. The clinician determines that parenteral antihistamine administration is appropriate for rapid symptomatic relief due to nausea and inability to tolerate oral medication. The clinical workflow includes: triage and vital signs, clinical assessment and indication verification, informed consent for injection, preparation of J0945 (injection, brompheniramine maleate, per 10 mg), administration via intramuscular or subcutaneous route by a licensed clinician, post-injection monitoring for 15–30 minutes for adverse reactions, documentation of lot number and dose in the medical record, and billing using J0945 with appropriate modifier(s) to reflect circumstances such as bilateral procedures, outpatient hospital site, or service interruptions. Typical sites of service are outpatient infusion clinics, urgent care centers, emergency departments, and physician offices. The typical patient scenario includes patients with acute allergic reactions, severe allergic rhinitis, or intolerance to oral antihistamines requiring injectable antihistamine therapy; comorbidities such as asthma or prior anaphylactic history may alter monitoring and site selection.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |